2017 Scientific Year in Review Webinar

2017 Scientific Year in Review Webinar - Cohen Veterans Bioscience Webinar Series

2017 Scientific Year in Review Webinar

Thursday, December 21, 2017, at 12pm noon ET

Magali Haas, MD, PhD
CEO & President, Cohen Veterans Bioscience

Webinar Summary

Join us for our 2017 Scientific Year in Review Webinar on December 21, 2017, which will cover our research progress towards developing diagnostics & personalized therapeutics for PTSD, TBI and other Brain Disorders.

Across medicine, a new understanding of the biology underlying illness is producing revolutionary treatments for cancer and other diseases that were once considered incurable. At the same time, advances in genetic analysis, imaging and computing are making the living human brain more accessible to science than ever before. These developments provide a golden opportunity to develop new diagnostics and treatments for the constellation of trauma-related conditions that affect veterans and civilians. This webinar will review our research progress in 2017.


About Magali Haas, MD, PhD
CEO & President, Cohen Veterans Bioscience

Magali Haas, MD, PhDDr. Haas founded Orion Bionetworks in July 2012 and serves as its CEO and President. Orion Bionetworks was transformed to Cohen Veterans Bioscience in 2015 to specifically dedicate research to improving the detection and treatment of post-traumatic stress (PTS) and traumatic brain injury (TBI) and related co-morbidities so that the burden of these conditions may be lessened on service members, veterans, and their families.

Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder.

She served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program.

As an “intrapreneur” at J&J she established the first Neuroscience Translational Medicine & Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. She serves on several advisory boards including Brain Canada, Prophase, Pear Therapeutics, PAASP and IMEC for nanoelectronics.

Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, New Jersey, and her MD PhD with distinction in neuroscience from Albert Einstein College of Medicine, New York.